ClinicalTrials.gg
Active, not recruitingNCT06029660Updated Jul 10, 2026

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

An interventional study of IMPEDE-FX RapidFill Implants and EndoVascular Aneurysm Repair in Aortic Aneurysm, Abdominal, sponsored by Shape Memory Medical, Inc.. Active, not recruiting at 49 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Shape Memory Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.

Planned enrollment
31st of 85
180 · median 94
Started
2024
with 5 others
No phase
64 of 122
14 open now
Primary completion
2027-07
later than 14 of 33 live
Registered
109th of 122
by date

Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 31st largest by planned enrollment of the 85 interventional ones that give a count, is one of 6 that started in 2024, is one of 64 with no phase, reaches primary completion later than 14 of the 33 other live ones, and was the 109th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Aortic Aneurysm, Abdominal with a site in United States, or all of them as a file.
02

Study summary

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.

03

Conditions studied

  • Aortic Aneurysm, Abdominal

Keywords

  • Abdominal Aortic Aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age
  2. A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women;
  3. Thrombus burden (percentage of the AAA sac occupied by thrombus) \<50%, based on pre-procedure CTA
  4. Maximum Lumen diameter within the AAA sac of ≥40mm.
  5. The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200.

Exclusion criteria

Exclusion Criteria:

General

  1. An inability to provide .
  2. Enrolled in another clinical study that could interfere with the outcomes being studied in this trial.
  3. Unable or unwilling to comply with study follow-up requirements.
  4. Prisoner or member of other vulnerable population

Anatomical

  1. Concomitant iliac artery ectasia or aneurysm
  2. Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the product into the AAA sac.
  3. Ruptured, leaking, inflammatory or mycotic (infected) aneurysm.
  4. Connective tissue disorder (e.g., Marfan's syndrome)
  5. Aneurysmal disease of the descending thoracic aorta
  6. Excessive calcification at the aortic bifurcation to common/internal iliac bifurcation, that might lead to access difficulties

EVAR/Procedural

  1. Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Gore Excluder Conformable AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II and Endurant IIs Stent Graft, or the Terumo TREO Stent Graft to treat the AAA
  2. Use of an aortic stent graft other than those specified1 for a particular site
  3. Planned use of the chosen stent graft outside its instructions for use (IFU)
  4. Use of fenestrated stent grafts or chimney techniques
  5. Use of the Heli-FX EndoAnchor system
  6. Use of embolic devices other than the investigational product to embolize the AAA sac
  7. Use of embolic products to prophylactically or concomitantly embolize the inferior mesenteric artery, lumbar arteries, renal accessory arteries, or internal iliac arteries
  8. Inability to land the distal-most portion of the EVAR stent graft limbs, including extensions, above the internal iliac arteries

Medical History/Conditions

  1. Coagulopathy or uncontrolled bleeding disorder
  2. Serum creatinine level >2.5 mg/dL
  3. Cerebrovascular accident within 3 months prior to the procedure
  4. Myocardial infarction and/or major heart surgery within 3 months prior to the procedure
  5. Atrial fibrillation that is not well rate controlled
  6. of \<2 years post-procedure
  7. Known or to platinum, iridium, or polyurethane.
  8. Have active infection at the time of the index procedure documented by pain, fever, drainage, positive culture, or leukocytosis (WBC >11,000/mm3)
  9. A condition that inhibits radiographic visualization during the implantation procedure
  10. History of allergy to contrast medium that cannot be managed medically, or subject is unable to have a CT with contrast for any reason.
  11. Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the trial
  12. Pregnant or lactating female: for females of , based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of for the duration of the trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Treatment

    Treatment Arm: Subjects in the treatment arm will have both an EVAR device and IMPEDE-FX RapidFill implants inserted.

    Device: IMPEDE-FX RapidFill Implants · Procedure: EndoVascular Aneurysm Repair

  • Active comparator
    Control

    Control Arm: Subjects in the control arm will only have an EVAR device implanted.

    Procedure: EndoVascular Aneurysm Repair

Interventions

  • DeviceIMPEDE-FX RapidFill Implants

    Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants

  • ProcedureEndoVascular Aneurysm Repair

    Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.

    Also known as: EVAR

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint : AAA Sac Regression at 1 year

    The percentage of subjects showing regression, defined as sac volume reduction of ≥10% at 1 year (in comparison to the 30 day CT), and no AAA-related intervention through 1 year.

    Time frame: 1 year

  2. Primary Safety Endpoint : Major Adverse Event (MAE) Rate through 30 days

    Freedom from the following through 30 days post-index procedure: * Major adverse events (MAEs) which include the following: all-cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, procedural blood loss \>1000 mL. * AAA-rupture or AAA-perforation * Conversion to Open Repair

    Time frame: 30 days

07

Study locations

49 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 73. This study's planned 39 months is close to that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 8, 2023
StartActual
Apr 5, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2031
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029660
Lead sponsor
Shape Memory Medical, Inc.
Collaborators
NAMSA
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Apr 5, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2031 (estimated)
Last update
Jul 10, 2026

Study contacts

Marc Schermerhorn, M.D.
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion